JP2021521200A5 - - Google Patents

Info

Publication number
JP2021521200A5
JP2021521200A5 JP2020555883A JP2020555883A JP2021521200A5 JP 2021521200 A5 JP2021521200 A5 JP 2021521200A5 JP 2020555883 A JP2020555883 A JP 2020555883A JP 2020555883 A JP2020555883 A JP 2020555883A JP 2021521200 A5 JP2021521200 A5 JP 2021521200A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020555883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/026788 external-priority patent/WO2019199972A1/en
Publication of JP2021521200A publication Critical patent/JP2021521200A/ja
Publication of JP2021521200A5 publication Critical patent/JP2021521200A5/ja
Pending legal-status Critical Current

Links

JP2020555883A 2018-04-10 2019-04-10 癌の処置のための化合物 Pending JP2021521200A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862655431P 2018-04-10 2018-04-10
US62/655,431 2018-04-10
PCT/US2019/026788 WO2019199972A1 (en) 2018-04-10 2019-04-10 Compounds for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2021521200A JP2021521200A (ja) 2021-08-26
JP2021521200A5 true JP2021521200A5 (enExample) 2022-04-19

Family

ID=68164559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555883A Pending JP2021521200A (ja) 2018-04-10 2019-04-10 癌の処置のための化合物

Country Status (6)

Country Link
US (1) US11530207B2 (enExample)
EP (1) EP3781564B1 (enExample)
JP (1) JP2021521200A (enExample)
KR (1) KR20200142039A (enExample)
CN (1) CN112272666A (enExample)
WO (1) WO2019199972A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
CN113692402A (zh) * 2019-02-04 2021-11-23 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN114126613A (zh) * 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN113677342A (zh) * 2019-02-05 2021-11-19 斯基霍克疗法公司 用于调节剪接的方法和组合物
KR20210134657A (ko) * 2019-02-05 2021-11-10 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
EP3920915A4 (en) 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021071983A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
WO2021071984A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
WO2021071981A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
CA3169697A1 (en) 2020-02-28 2021-09-02 Dominic Reynolds Thiophenyl derivatives useful for modulating nucleic acid splicing
MX2022010634A (es) 2020-02-28 2023-01-19 Remix Therapeutics Inc Derivados de piridazina para modular el empalme de acidos nucleicos.
WO2021174167A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Compounds and methods for modulating splicing
JP7736700B2 (ja) 2020-02-28 2025-09-09 リミックス セラピューティクス インコーポレイテッド 複素環アミド及びスプライシングを調節するためのその使用
KR20230005210A (ko) 2020-04-08 2023-01-09 레믹스 테라퓨틱스 인크. 스플라이싱을 조절하기 위한 화합물 및 방법
JP2023520916A (ja) 2020-04-08 2023-05-22 リミックス セラピューティクス インコーポレイテッド スプライシングを調整するための化合物及び方法
EP4178963A1 (en) 2020-07-02 2023-05-17 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
EP4175956A1 (en) 2020-07-02 2023-05-10 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
CN116940578A (zh) * 2020-07-02 2023-10-24 雷密克斯医疗公司 5-[5-(哌啶-4-基)噻吩并[3,2-c]吡唑-2-基]吲唑衍生物和相关化合物作为调节剂用于剪接核酸和治疗增殖性疾病
EP4192454B1 (en) * 2020-08-05 2026-04-22 Skyhawk Therapeutics, Inc. Azabicyclo-amino-triazine compounds for modulating splicing for the treatment of neurological diseases
WO2022060951A1 (en) * 2020-09-16 2022-03-24 Skyhawk Therapeutics, Inc. Compositions for modulating splicing
GB2603454A (en) * 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
CN112662780A (zh) * 2021-01-29 2021-04-16 复旦大学附属中山医院 检测hnrnpm表达的试剂在制备诊断和/或预后判断肝癌中的应用及药物组合物
US20240400584A1 (en) 2021-08-30 2024-12-05 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20240368163A1 (en) 2021-08-30 2024-11-07 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034836A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034812A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
IL311132A (en) 2021-08-30 2024-04-01 Remix Therapeutics Inc Splicing Modulation Compounds and Methods
CA3233973A1 (en) 2021-10-13 2023-04-20 Dominic Reynolds Compounds and methods for modulating nucleic acid splicing
WO2023064879A1 (en) 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
US20250109140A1 (en) 2022-01-05 2025-04-03 Remix Theraputics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
US20250326748A1 (en) 2022-01-05 2025-10-23 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023133217A1 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5128118A (en) * 1990-08-09 1992-07-07 Research Triangle Institute Cocaine receptor binding ligands
US7189737B2 (en) * 1991-08-09 2007-03-13 Research Triangle Institute Cocaine receptor binding ligands
GB0311201D0 (en) 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
ATE493415T1 (de) 2004-10-20 2011-01-15 Neurosearch As Neue diazabizyklische arylderivate und medizinische verwendung dafür
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
FR2926297B1 (fr) * 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
CA2719735A1 (en) * 2008-03-27 2009-10-01 Gruenenthal Gmbh Substituted 4-aminocyclohexane derivatives
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
WO2015024876A2 (en) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Screening method
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
EP3053577A1 (en) * 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
EP4249472A3 (en) * 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
KR20200057071A (ko) 2017-09-25 2020-05-25 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물

Similar Documents

Publication Publication Date Title
JP2021521200A5 (enExample)
JP7652697B2 (ja) ピリダジン系誘導体阻害剤、その製造方法及び使用
CN116199703A (zh) 稠合四环杂环化合物、其制备方法及其在医药上的应用
AU2006212761B2 (en) Combination therapy
TW202322819A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
CN118176198A (zh) 含氮的四环化合物、其制备方法及其在医药上的应用
WO2023143312A1 (zh) 一种含氮杂环化合物、其制备方法及应用
JP2020528889A5 (enExample)
JP2020537657A5 (enExample)
RU2004117887A (ru) Ариланилиновые агонисты бета2 адренергических рецепторов
TWI570109B (zh) Preparation of aromatic heterocyclic compounds as selective JAK3 and / or JAK1 kinase inhibitors and their use
WO2022105771A1 (zh) 含氮杂环类衍生物、其制备方法及其在医药上的应用
WO2019137201A1 (zh) 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
JP2023511222A (ja) 置換ピリダジノン類化合物とその用途
TW201737943A (zh) 使用fasn抑制劑之方法
WO2021227938A1 (zh) 含非甾体抗炎药结构的氨基酸衍生物及其制备方法与应用
WO2021170811A1 (en) Method of treating eye disease using trpv4 antagonists
JP2023503482A (ja) Jak阻害剤としての三複素環式化合物及びその使用
CN105658634B (zh) 作为TCR-Nck相互作用的抑制剂的被醇盐取代的色烯衍生物
WO2022214937A1 (en) Substituted tetracyclic carboxylic acids, analogues thereof, and methods using same
JP2024505912A (ja) 連環を含むtyk2阻害剤化合物
JP2000516257A (ja) タキキニンアンタゴニスト
US20250115596A1 (en) Esters of 8-methyl-8-azabicyclo[3.2.1] octan-3-yl 3-hydroxy-2-phenylpropanoate
CN118339149A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
JP2023002841A (ja) 高血圧症及び/又は線維症を処置するための組成物